Over the past six months (April 2026 - October 2026), Silicon Laboratories experienced several significant stock events. On May 5, 2026, Q1 2026 earnings were released, reporting $214 million revenue (up 20% year-over-year) and $0.53 non-GAAP diluted EPS, with accelerated bookings and declining inventory. The major news of Texas Instruments' intent to acquire Silicon Labs for $231.00 per share, announced on February 4, 2026, significantly impacted the stock, causing a 48.45% surge on that day and pushing shares over $205 due to a 68% premium. This $7.5 billion all-cash transaction is expected to close in the first half of 2027, pending regulatory approvals, particularly from China's SAMR, which has caused delays. The Hart-Scott-Rodino Antitrust waiting period expired on May 22, 2026, advancing the acquisition. On April 30, 2026, Dr. Aslam Rafi was promoted to Senior Fellow. Q2 2026 financial results, released on August 11, 2026, showed revenue of $228 million (up 18% year-over-year) and non-GAAP diluted EPS of $0.71, surpassing estimates, with strong growth in Industrial & Commercial (23% year-over-year), Home & Life (12% year-over-year), and record Medical applications revenue (78% year-over-year). Analyst ratings in October 2026 saw Wall Street Zen upgrade SLAB to a 'Hold,' though the broader consensus remains 'Reduce,' with Zacks Research downgrading to a 'strong sell' in August and Weiss Ratings restating a 'sell' in September. The stock price increased by 69.05% over the last 12 months, with a year-to-date return of 70.33% as of October 6, 2026, closing at $222.04 on October 9, 2026.
